生物制剂作为银屑病一线系统治疗:BADBIR目标试验模拟队列研究
本研究基于BADBIR登记数据,采用目标试验模拟框架,纳入3702例未接受过系统治疗的中重度银屑病成人患者,比较一线使用生物制剂与标准阶梯治疗(先传统系统药、必要时再换生物制剂)的5年疗效与共病风险。结果显示,一线生物制剂组PASI与DLQI更低、完全清除率更高,慢性共病风险更低。
要点
- 一线生物制剂组5年PASI和DLQI均低于标准治疗组
- 一线生物制剂组达到PASI 0的累积率更高(HR 2.85)
- 一线生物制剂组慢性共病风险更低,精神与肝脏疾病风险下降
核心结论
- 以生物制剂作为首个系统治疗与更优的临床结局相关,支持重新考虑现有治疗路径以允许更早使用生物制剂。
研究设计与样本
- 纳入≥18岁、基线PASI≥10且未接受过系统治疗的中重度银屑病患者。
- 共纳入3702例,其中3368例接受标准治疗,334例以生物制剂为一线系统治疗。
- 采用混合效应重复测量模型分析5年PASI与DLQI轨迹,采用边际结构模型加稳定逆概率加权估计完全清除概率与共病风险。
主要发现
- 5年时平均PASI:标准治疗组4.7(95%CI 4.0-5.4),生物制剂起始组2.0(1.2-2.7)。
- 5年时DLQI:标准治疗组5.6(4.2-7.0),生物制剂起始组3.5(1.3-5.7)。
- 达到PASI 0的累积率:标准治疗组32.2%,生物制剂起始组58.6%;生物制剂起始组达PASI 0可能性更高(HR 2.85,95%CI 2.34-3.47)。
- 慢性共病累积风险:生物制剂起始组47.5%,标准治疗组54.3%;HR 0.72(95%CI 0.58-0.89)。
- 精神疾病风险HR 0.64(95%CI 0.44-0.94),肝脏疾病风险HR 0.54(95%CI 0.38-0.76)。
关键数值与推荐
- 中重度银屑病定义:基线PASI≥10。
- 主要疗效指标为5年PASI与DLQI轨迹、PASI 0累积率。
- 共病结局包括心血管、肝脏、肿瘤、代谢、精神、肌肉骨骼疾病及新发银屑病关节炎。
临床怎么用
- 对未接受过系统治疗的中重度银屑病患者,可考虑更早启用生物制剂以改善皮损与生活质量。
- 早期生物制剂治疗可能降低部分长期共病风险,尤其是精神与肝脏疾病。
- 临床决策仍需结合患者个体情况与现有治疗路径。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current treatment pathways for moderate-to-severe psoriasis in the United Kingdom and the Republic of Ireland direct initiation of targeted biologic immunomodulators when conventional systemic drugs are ineffective or not tolerated. Starting biologics early in the treatment pathway may modify the disease course and improve short- and long-term outcomes. OBJECTIVE: To compare the effectiveness and risk of incident comorbid conditions over five years between initiating a biologic as the first systemic treatment and the standard-of-care (beginning with conventional non-biologic systemic therapy with possible subsequent switch to biologics). METHODS: This study applied the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from September 2007 to December 2024. Adults (≥18 years) with moderate-to-severe psoriasis (baseline Psoriasis Area and Severity Index [PASI] ≥10) and no prior systemic therapy were included. Five-year trajectories of PASI and Dermatology Life Quality Index (DLQI) were modelled using mixed-effects repeated-measures models (MMRM). The probability of complete skin clearance (PASI = 0) and the risk of developing long-term comorbidities (cardiovascular, hepatic, neoplastic, metabolic, mental health, musculoskeletal disorder conditions, and incident psoriatic arthritis) were estimated using marginal structural models with stabilised inverse probability weighting to adjust for baseline and time-varying confounding. RESULTS: We included 3,702 patients, 3,368 followed standard-of-care, and 334 initiated a biologic as first-line systemic therapy. At 5 years, mean PASI from MMRM was 4.7 (95% confidence interval [CI] 4.0-5.4) for standard-of-care and 2.0 (1.2-2.7) for biologic initiators; DLQI was 5.6 (4.2-7.0) and 3.5 (1.3-5.7), respectively. Cumulative rate of achieving PASI 0 was 32.2% versus 58.6%, with higher likelihood of PASI 0 for biologic initiators (hazard ratio [HR] 2.85, 95% CI 2.34-3.47). The cumulative risk of chronic comorbidities was lower among biologic initiators (47.5% vs 54.3%; HR 0.72, 95% CI 0.58-0.89), with lower risks of mental disorders (HR 0.64, 95%CI 0.44-0.94) and hepatic disorders (HR 0.54, 95%CI 0.38-0.76). CONCLUSION: Initiating biologics as the first systemic therapy was associated with better clinical outcomes compared with standard stepwise approaches. These results support reconsideration of existing pathways to allow earlier use of biologics.
引用
- Phan DB, Laws P, Smith CH, et al. Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2026. PMID: 41834103. doi:10.1093/bjd/ljag098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。